Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) FCF Margin (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed FCF Margin for 9 consecutive years, with 7.81% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 1440.0% year-over-year to 7.81%, compared with a TTM value of 19.84% through Sep 2025, up 1955.0%, and an annual FY2024 reading of 40.68%, down 392.0% over the prior year.
  • FCF Margin was 7.81% for Q3 2025 at Sunshine Biopharma, up from 15.23% in the prior quarter.
  • Across five years, FCF Margin topped out at 7.81% in Q3 2025 and bottomed at 1192.65% in Q3 2021.
  • Average FCF Margin over 5 years is 324.89%, with a median of 59.68% recorded in 2024.
  • Peak annual rise in FCF Margin hit 114713bps in 2021, while the deepest fall reached -62889bps in 2021.
  • Year by year, FCF Margin stood at 366.68% in 2021, then skyrocketed by 83bps to 61.95% in 2022, then soared by 52bps to 30.04% in 2023, then dropped by -22bps to 36.63% in 2024, then skyrocketed by 79bps to 7.81% in 2025.
  • Business Quant data shows FCF Margin for SBFM at 7.81% in Q3 2025, 15.23% in Q2 2025, and 19.34% in Q1 2025.